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Think not those faithful who praise all thy words and 
actions; but those who kindly reprove thy faults. 
Socrates (469 BC-399 BC) 
To My Mother, Father, Marina, Yasmin and Nicki 
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2. Abbreviations 
A adrenaline 
ACA adrenocortical adenoma 
ACC adrenocortical carcinoma 
CA catecholamines 
CAM cell adhesion molecule 
CgA chromogranin A 
CT computed tomography 
DA dopamine 
DHEA dehydroepiandrosterone 
ECAD E-cadherin 
ICD international classification of diseases 
MEN 2 multiple endocrine neoplasia 2 
MIBG meta-iodo benzyl guanidine 
MRI magnetic resonance imaging 
MTC medullary thyroid cancer 
NA noradrenaline 
NCAD N-cadherin 
NCAM neural cell adhesion molecule 
NCR national cancer registry 
NF1 neurofibromatosis type 1 
o, p'-DDD 1,1- dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane 
PC pheochromocytoma 
PET positron emission tomography 
PG paraganglioma 
pbz phenoxybenzamine 
RIA radioimmunoassay 
TH tyrosine hydroxylase 
VHL von Hipple-Lindau's disease 
VMA vanillyl mandelic acid 
VRD von Recklinghausen's disease 
WB western blotting 
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3. Abstract 
Adrenocortical Carcinoma (ACC) is a rare malignant tumour with poor prognosis. Surgical 
removal is the only cure. Adjuvant use of mitotane, an adrenolytic drug with toxic effects, is 
controversial at best. We evaluated our treatment program for patients with ACC including 
active surgery, adjuvant mitotane treatment monitored by serum levels of the drug, and 
urinary steroid profiles in the follow-up to detect early recurrences. Monitoring of serum 
levels of mitotane made long-term treatment possible in advanced disease with moderate side 
effects. Repeat surgery for recurrence was valuable in patients with long disease-free 
intervals, and urinary steroid profiles indicated early recurrence in individual patients. The 5-
year survival of 30 consecutive patients with ACC (44% low Stage and 56% high Stage 
tumours) in our series was 64%. Patients with high Stage ACC (Stage III-IV), treated with 
mitotane after surgery, seemed to have better prognosis than expected. The results of 
cytotoxic treatment in advanced disease, using single or multiple cytotoxic agents, have so far 
been disappointing. Better results were obtained when mitotane was combined with the 
chemotherapy. Multicenter trials are needed in order to find the best combined medical 
therapy for these patients. 
In order to find histopathological markers that can predict the prognosis in ACC and 
pheochromocytoma (PC), 87 adrenal tumours were analysed for the expression of cell 
adhesions molecules by immunocytochemistry and Western blotting. Both cortical and 
medullary adrenal tumours expressed NCAD, NCAM and CD44, but all tumours were devoid 
of ECAD. The expression of CD44 and NCAM did not correlate with the malignant potential 
of the tumours. During cell transformation and tumour progression NCAD expression seemed 
to be up-regulated in medullary tumours, but down-regulated in cortical tumours. Loss of 
NCAD may thus be involved in the development of malignant adrenocortical tumours. Thus, 
NCAD may function as tumour suppressor and lack of its expression may be of prognostic 
significance in adrenocortical tumours. 
PC and paraganglioma (PG) rarely metastasize, but may still be life-threatening due to 
excessive secretion of catecholamines (CA). The cause of death in untreated PC/PG is 
hypertensive complications and in rare cases metastatic disease. The overall prognosis after 
surgical removal of PC has not been studied in detail. In the present study with long-term 
follow-up (1950-1997), 121 consecutive cases of surgically treated PC/PG were reviewed in 
order to evaluate outcome, cause of death and histopathological features. There was no intra-
or post-operative mortality. Eight patients proved to have malignant PC/PG during the period. 
The number of deaths in the series was higher than expected in the general population (p 
<0.001). The main causes of death were cardiovascular and other tumour diseases. High age 
at primary surgery and high urinary excretion of methoxy-CA were significant risk factors for 
death. For comparative reasons, all cases with adrenal PC, diagnosed in Sweden 1958-1997, 
were investigated. Patients in the national cohort had almost 4 times higher risk for death in 
tumour diseases than the general population, but no elevated death risk for cardiovascular 
diseases. Life-long follow-up of these patients is important not only to diagnose and treat 
cardiovascular diseases and recurrent PC at early Stage, but also to diagnose other tumour 
diseases. 
ISBN: 91-628-6036-4 
9 
4. Introduction 
Primary tumours in adrenal glands are derived from the cortex [adrenocortical adenomas 
(ACA) and adrenocortical carcinomas (ACC)] or from the medulla [benign and malignant 
pheochromocytomas (PC)]. Extra-adrenal PC or paraganglioma (PG), with catecholamine 
(CA) production are localised in the chromaffin tissue of paraganglia located outside the 
adrenal glands. 
4.1 Adrenocortical carcinoma 
4.1.1 Epidemiology. ACC is a rare and aggressive tumour with an incidence of 0.5-2.0 per 
million inhabitants a year and slight female preponderance. The age distribution is bimodal 
with a first peak early in childhood and a second larger peak around the age of 40-50 yr 
( Woolen et al 1993, Schulick et al 1999, Dackiw et al 2001). 
4.1.2 Clinical presentation and diagnosis. The disease is often advanced at the time of 
diagnosis and the patient may present with an abdominal mass. More than half of the patients 
have functional tumours with hormonal symptoms and may be detected earlier (Icard et al 
1992, Luton et al 1999, Norton 1999, Kopf et al 2001). There are no absolute radiological 
diagnostic criteria of ACC. Irregular shape and margins; non-homogenous density and 
presence of haemorrhage/necrosis on CT should alert the clinician. The MRI criteria include 
lack of fat suppression on out of phase images, heterogeneous T2 signalling, gadolinium 
enhancement and slow wash-out (Korobkin 2000, Barnett et al 2000). Early reports on very 
sensitive detection of ACC using HC-metomidate as tracer for Positron Emission 
Tomography (PET) are promising (Khan et al 2003). Fine needle aspiration biopsy is not 
entirely reliable in distinguishing between benign and malignant adrenocortical tumours. It 
can be of value to diagnose adrenal metastases from other primaries, e.g. lung cancer or 
melanomas. In these cases PC must be excluded prior to biopsy. Capsular disruption of an 
aggressive tumour like ACC by biopsy may lead to dissemination of the tumour disease 
(Dackiw et al 2001). 
Due to increased use of CT several adrenal tumours are detected incidentally. All functional 
tumours are operated, but among the non-functional ones there is always a fear to miss an 
ACC. Large tumour mass is one indicator of ACC. Copeland (1983) performed one of the 
first studies on the relation between tumour size and malignancy in adrenocortical tumours. In 
a survey of 114 ACC 92% were larger than 6 cm in diameter. Ross & Aron (1990) indirectly 
estimated that less than 1% of ACA were larger than 6 cm in size. Terzolo et al (1997) studied 
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a large group of patients with non-functional incidentalomas (n=210); 115 patients were 
operated and 15 were diagnosed as ACC. Of these only three were smaller than 6 cm in size. 
The 5 cm limit to identify ACC had a sensitivity of 93% and a specificity of 64%. From the 
same time period they studied 16 functional ACC; none was smaller than 6 cm. The proposed 
5 cm limit was also tested in 38 consecutive cases of ACC from M.D. Anderson Cancer 
Center. Actually 5 of these tumours were smaller than 5 cm; 4 with "malignant" radiology 
and one functional tumour (Barnett et al 2000). To date more than 40 patients with ACC 
smaller than 5 cm have been reported (the smallest 1 cm) in the literature. ACC only rarely 
secrete aldosterone, but Farge et al (1988) described 2 cm aldosteronoma to be ACC, which 
means that our clinical rules and measures will never be absolute. 
4.1.3 Urinary steroid profiles. In neoplasia, mutations of the adrenal cortical cells may lead 
to absolute or relative enzymatic deficiencies in the steroid metabolic pathway (Figure 1). 
Figure 1: Pathways of adrenal steroid biosynthesis and metabolism 
CHOLESTEROL 
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ANDROSTERONE 
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This in turn may lead to abnormal steroid intermediates or metabolites in urine, which can be 
detected by gas chromatography/mass spectrometry. Some of these steroids seem to be more 
common in patients with ACC than in benign adrenocortical diseases and healthy subjects, 
e.g. increased secretion of 11-deoxytetrahydroxycortisol (THS) and/or 3 ß-hydroxy-5-ene 
steroids (Lipsett et al 1963, Gröndal et al 1990). Excretion of THS and metabolites of Cortisol 
precursors have been found in both functional and non-functional ACC (Gröndal et al 1990). 
The steroid profiles may differ between primary and recurrent disease and during 
chemotherapy, which indicates that analysis of a single steroid as a tumour marker of 
recurrent disease is not sufficient. Repeated analysis of urinary steroid profiles is a tool with 
the potential of early identification of recurrent disease, but is limited by lack of age- and sex 
related reference values and strict definition of pathological intermediates (cf. Weykamp et al 
1989, Honour et al 1997). Patients with inborn deficiencies of steroid hydroxylase and 3ß-
hydroxysteroid dehydrogenase/A3"4 isomerase also have aberrant steroid profiles. Likewise, 
women with hirsutism and polycystic ovary syndrome may have increased 3ß-hydroxy-5-ene 
steroids. These conditions may thus be a differential diagnostic problem in patients with 
suspicion of ACC (Gröndal et al 1990). 
4.1.4 Staging. The prognosis in ACC largely relates to tumour Stage (Icard et al 2001), 
which was originally defined by McFarlane and later modified by Sullivan (Sullivan et al 
1978) (Figure 2). 
Figure 2: Tumour staging of ACC according to McFarlane, modified by Sullivan 
Tumour < 5 cm and confined to the adrenal 
Tumour > 5 cm and confined to the adrenal 
Tumour of any size with lymph node metastases or local invasive growth (i.e. tumour 
growth outside the adrenal but not involving adjacent organs) 
Tumour of any size with lymph node metastases and local invasive growth, growth into 
adjacent organs, or distant metastases 
The accuracy of diagnosis in Stage I has be en questioned; in some series small adrenocortical 
tumours are referred to as "atypical adenomas" due to atypical histology, but with uncertain 
malignant potential. Inclusion of potentially benign lesions, classified as Stage I ACC has 
impact on the survival analysis (Proye 1997, Norton 1999). Icard et al (1992) and Lee et al 
(1995) proposed a modification of the classification so that patients with locally advanced 
ACC were Stage III and those with metastatic disease were Stage IV. Th is modification has 
been suggested to more accurately reflect the natural history of ACC with closer correlation to 
I Stage I 
I Stage II 
1 Stage III 
I 
I j Stage IV 
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other staging systems used for solid tumours (Dackiw et al 2001). Furthermore, tumours with 
isolated growth into the caval vein seem to have better prognosis than Stage IV tumours 
{Norton 1999). 
4.1.5 Criteria for malignancy. The size of an adrenal tumour is one good predictor of 
malignancy with a cut-off limit of >4 cm for interventions (Dackiw et al 2001). Smaller 
tumours can be clinically difficult to determine in terms of malignancy (Proye 1997). The 
histopathological diagnosis of ACC can be difficult; the only definite criterion for malignancy 
is then occurrence of metastases and/or local invasiveness (Pommier et al 1992, Proye 1997, 
Lack 1997). Local recurrence has been proposed as a criterion for malignancy. However, this 
is controversial since capsular rupture of a benign tumour intraoperatively may result in local 
seeding, growth and invasion (Proye 1997). Histological indexes of malignancy to predict 
prognosis have been proposed ( Weiss 1984, Weiss et al 1989) (Figure 3). 
Figure 3: Histopathological scoring system for ACC 
* 1 
1 '• Diffuse architectural pattern with broad 5. Vascular invasion 
I fibrous and trabecular bands 6. Nuclear grade III or IV 
2. Focal necrosis 7. Atypical mitosis 
1 
3. Invasion of sinusoidal structures 8. High mitotic rate 
4 ä Capsular invasion 9. Clear cells constituting <25% of the tumour 
None of the criteria suggested are diagnostic alone, but the possibility of malignancy 
increases with the presence of two, or more, criteria (Proye 1997). In a recent study 24 ACC 
with distant metastases or gross local invasion, or recurrence, were selected and matched with 
25 benign AC A. Presence of >3 Weiss criteria was related to malignancy with 100% 
sensitivity and 96% specificity, further corroborating the use of the Weiss system (Aubert et 
al 2002). 
4.1.6 Surgical treatment. Surgery is the standard treatment for resectable primary and 
secondary adrenal tumours and also for recurrent disease. For patients with low Stage (I & II) 
tumours and certain high Stage tumours resection is the only way to cure. With invasive 
tumour, or metastatic disease (III & IV), en bloc excision of other organs can be necessary 
(Norton 1999). The overall 5-year survival following resection varies largely between series 
(38-62%) (Lee et al 1995, Schulick et al 1999). If repeat surgery for local recurrence or 
metastases can be performed, it can palliate hormonal symptoms in patients with functional 
tumours, but the important question is whether it can prolong survival for the majority of 
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ACC patients. The first large series from France reported on the clinical outcome of 156 ACC 
patients (Icard et al 1992). Low Stage tumours were equally common as high Stage tumours 
(53 v.v. 47%). Complete resection was performed in 81%. However, only 22 patients had 
resection for local recurrence with a 5-year survival of 16% after the re-operation. With 
reservation for selection bias somewhat better 5-year survival (28%) was achieved when 
complete resection of the recurrence could be done. The Italian national series of 179 ACC 
patients (Bellantone et al 1997) had a similar distribution of low- and high Stage tumours (51 
vs. 49%) and similar rate of complete resections (80%). Recurrences were seen in 52 patients 
after a mean disease-free interval of 22 mos. It was three times more common to have distant 
metastases, or a combination of local recurrence and distant metastases, than local recurrence 
alone. Repeat surgery was performed in a selected group of 20 patients with a 5-year survival 
of 50% vs. 8% in 32 patients not resected. The consecutive series from one single centre 
[Memorial Sloan Kettering Cancer Center (MSKCC)] equals many of the national series in 
size (n=l 13). The ratio between low- and high-Stage tumours was 1:1. The resection rate was 
somewhat lower (60%) than in the national series, probably reflecting the status of MSKCC 
as nationwide referral centre. The resection rate for recurrent disease was very high. Second 
resection was performed in 46 patients with clear survival advantage in those with complete 
resection; 32 patients with complete resection had a 5-year disease-specific survival o f 57% 
vs. 0% in 15 patients with incomplete resection (Schulick et al 1999). Complete resections 
were most common in p atients with discrete distant metastases, e.g. lesions in the lungs and 
liver. B ulky local rec urrences were one reason for incomplete resections. The active attitude 
for repeat surgery in this s eries is ref lected by the fact t hat 47 patients had 107 resections; 
individual patients with complete re-resection could have several repeat interventions to 
remain tumour-free. When the disease-specific survival after complete repeat surgery was 
stratified by type of recurrence, there was a small non-significant survival advantage for those 
with distant metastases vs. those with local recurrences. 
4.1.7 Medical treatment, a) Mitotane. Mitotane (o, p'- DDD) is an adrenolytic drug used for 
more than 40 yr as palliative and adjuvant therapy for patients with ACC. It causes se lective 
destruction of the zona fasciculata and reticularis layers of the adrenal cortex and inhibits the 
production of corticosteroids (11 ß -hydroxylation and cholesterol cleavage), but also the 
extraadrenal metabolism of steroids. ACC usually has a strong expression of the multi-drug 
resistance gene (MDR-1), which results in production of P-glycoprotein which facilitates 
efflux of cytotoxic agents. Mitotane potentially reverses this effect, which may favour 
combined treatment with mitotane and certain cytotoxic drugs (Bates et al 1991, Flynn et al 
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1992). The early high-dose (8-10 g) mitotane studies reported high tumour regression rates for 
patients with measurable disease at that time (Bergenstahl et al 1960, Hutter & Key hoe 1966, 
Lubitz et al 1973). Later trials showed much less convincing responses (Cohn et al 1986, 
Luton et al 1990, Wooten et al 1993, Baudin et al 2001). Treatment with mitotane reduced 
steroid hypersecretion in 75% of the patients in a recent study (Kopf et al 2001). Furthermore, 
one small study with low-dose mitotane (1-2 g), given as adjuvant to surgical resection, 
showed a 4-fold survival advantage over non-treated patients (Schteingart et al 1982). 
High-dose mitotane is often associated with severe side effects (gastrointestinal and 
neurological) and its role as adjuvant therapy after complete resection has been questioned 
(Barzon et al 1999, Kasperlik-Zaluska 2000). The response to mitotane has been suggested to 
be dose-related with a " therapeutic threshold" at mitotane levels of 14 lig/ml. No therapeutic 
effects were noted at levels below 10 |ig/ml, but the "therapeutic window" was narrow (<20 
|ig/ml) (van Slooten et al 1984, Haak et al 1994). With the option to monitor mitotane levels 
such therapy can today be individualized, avoiding unacceptable neuromuscular toxicity. In a 
rare disease like ACC the use of mitotane in adjuvant or palliative settings as single agent, or 
as part of combined chemotherapy requires international multicenter studies. Adjuvant use of 
mitotane has since the first report in 1982 generated a large number of studies (all small, 
single centre, or retrospective) with improved survival (van Slooten et al 1984, Venkatesh et 
al 1989, lcard et al 1992, Wooten et al 1993, Haak et al 1994, Kasperlik-Zaluska 2000), or no 
benefit (Luton et al 1990, Pommier et al 1992, Vassipoulou-Sellin et al 1993, Barzon et al 
1997). 
b) Cytotoxic agents. Several cytotoxic agents have been used as single or combination 
therapy to treat advanced ACC. However, since ACC are rare and aggressive tumours 
associated with short survival, the disease has not allowed adequate drug trials, especially not 
with delayed diagnosis or previous treatment using different strategies. After reviewing 
published data on chemotherapy, combined with mitotane, some treatments [Etoposide + 
Doxorubicin + Cisplatin (EDP) + mitotane] (Berruti et al 1998) and [streptozocin + mitotane] 
(Khan et al 2000) had response rates exceeding 30%. 
c) External radiation. This treatment modality has been used to palliate pain due to bone 
metastases. In limited studies, it was proven effective in the treatment of residual ACC 
(Markoe et al 1991, Schulick et al 1999). Its therapeutic potential has not been fully 
elucidated. 
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4.1.8 Prognostic factors. The overall 5 -year survival for patients with ACC varies between 
38-60%, but the disease is potentially curable at early Stage. However, up to 70% of ACC 
patients present with advanced disease ( Wooten et al 1993). The Stage of ACC has proven to 
be t he most important prognostic factor. Local i nvasion, or lymph node metastases, indicate 
poor prognosis, but the most severe factor is presence of distant metastases with a median 
survival of less than one year, not much changed over time (Sullivan et al 1978, Henely et a l 
1983, Brennan 1987, Luton et al 1990, Wooten et al 1993). In the French national series 
(n=253) the 5-year survival related to Stages was: Stage I (66%), II (58%), III (24%), and IV 
(0%) (Icard et al 2001). In a recent study of 105 patients the Weiss scores were also analysed: 
Stage I (100%), II (84%), III (33%), and IV (11%); patients with scores <3 had 100% 5-year 
survival, while those with scores >4 had a 62% survival strongly indicating the usefulness of a 
scoring system (Lucon et al 2002). In one large retrospective series young age, extent of the 
cancer, type of secretion and aspect of surgical resection seemed to favour survival, while sex, 
tumour size and weight had no influence (Icard et al 1992). 
Surgery remains the mainstay of treatment in resectable ACC and repeat surgery with 
curative intent is of value for extended survival New diagnostic tools to detect recurrent 
disease early are needed. For optimal medical treatment of advanced disease new treatment 
strategies must be addressed in prospective multicenter studies. The role of adjuvant 
mitotane after curative resection remains to be settled for both low and high Stage tumours. 
4.2 Cell adhesion molecules in adrenal tumours 
The biological behaviour of adrenal tumours is highly variable and the clinical outcome of an 
individual tumour can be difficult to predict. New markers that can distinguish between 
benign and malignant adrenal tumours are clearly needed. During the last decades several 
endocrine tumour markers have been discovered. Immunocytochemical studies have been 
performed to identify the distribution of markers in various tumour types. Tumours with 
different degree of differentiation have been studied to reveal possible molecular mechanisms 
behind progression. Cell adhesion molecules (CAM) are important for cell and tissue 
structure and integrity and play an important role in the tumorigenesis of many tumour types; 
dysregulation of CAM correlates with tumour de-differentiation, metastatic spread, and 
infiltrative tumour growth (Table 1). 
CAM are specific surface proteins, distributed throughout the cell membrane, which mediate 
cell-cell adhesion or cell-matrix interaction. Some of these proteins make connections with 
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the cytoskeleton, while others are involved in signal transduction pathways (Ikeguchi et al 
00). CAM can be divided into 4 major groups: Cadherins (calcium-dependent CAM), Ig-like 
CAM (non-calcium dependent), integrins, and selectins. The calcium-dependent Cadherins 
(e.g. ECAD, NCAD) and non-calcium dependent Cadherins (e.g. n eural-CAM, CD44) are 
directly involved in cell-cell interactions (Table 1). 
Table 1 : Characteristics of CAM analysed in this thesis 
CAM Type Examples of changed expression and possible clinical relevance 
Calcium 
dependent 
ECAD Loss of ECAD (Perl et al 1998. Christofen et al 1999. Ikeeuchi et al 2000). 
> Transition from adenoma to carcinoma; a factor behind invasiveness and 
metastasis formation in pancreatic cancer 
> A marker for poor prognosis in colorectal cancer 
NCAD NCAD exDression (Kim et al 2000. Kovacs et al 2003). 
> Up-rcgulation of NCAD (and down-regulation of ECAD) in squamous cell 
carcinoma; up-rcgulation of NCAD (but no down-regulation of ECAD) in 
breast cancer 
> Inappropriate expression leads to conversion of epithelial tumour cells into a 
fibroblast-like phenotype with increased motility & invasiveness 
Non-
calcium 
dependent 
NCAM Loss of NCAM (Perl et al 1999. Esni et al 1999). 
> Important for tumorigenesis and metastatic spread of endocrine pancreatic 
tumours 
CD44 CD44 expression (Lesley et al 1993. Peck et al 1998. Wallach-Davan et al 2001). 
> Malignant tumours, e.g. colon, gastric and breast cancers. 
> Associated with tumour progression and metastasis formation; lymphocyte 
homing to the inflammatory area and promotion of cell migration 
The role of CAM in adrenal tumours is not well understood. CD44 was studied in adrenal 
tumours; its cytoplasmic expression in ACC contrasted with its membranous staining in PC. 
Consequently, CD44 might be of value in distinguishing between these tumour types 
(Barshack et al 1998). The expression of ECAD seemed to have no diagnostic or prognostic 
value in adrenal medullary tumours (Gupta et al 2000). 
The expression of CAM and its pathophysiological role in adrenal tumours has not been 
fully evaluated. Some molecules may be helpful to distinguish between benign and 
malignant tumours. 
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4.3 Pheochromocytoma and paraganglioma 
4.3.1 Epidemiology. PC/PG is a rare tumour disease with an incidence of 1.5-1.9 cases per 
million inhabitants a year, most common between the ages of 30-50 yr (Kebebew et al 1998). 
PC/PG rarely metastasize, but may still be life-threatening due to excessive secretion of CA 
(Russell el al 1998). 
4.3.2 Clinical presentation and diagnosis. The diagnosis of PC is usually based on 
biochemical determination of CA, vanillylmandelic acid (VMA), and metanephrines in 24 h 
urinary collections. Recently it was shown that CA were metabolized to free metanephrines 
by tumour cells, independent of CA release, which makes free metanephrines in plasma the 
most sensitive biochemical test for PC/PG (Lenders et al 2002). 
Classical signs and symptoms related to high circulating levels of CA are hypertension, 
headache and excessive sweating (Goldstein et al 1999), which can occur attack-wise. 
Hypertension can also be sustained in about half of the patients (Plouin et al 1997, McClellan 
2002, Williams et al 2003). Cerebrovascular and cardiac accidents may occur during 
hypertensive crises (Russell et al 1998, Williams et al 2003). Since the disease is rare and the 
symptoms may be intermittent, typical symptoms can easily be neglected and the diagnosis 
delayed. In older patient series up to 40% of PC/PG were not diagnosed until autopsy 
(Stenström et al 1986). 
4.3.3 Genetics. PC/PG usually occur as sporadic tumours. Until recently 10% were supposed 
to be part of rare syndromes with autosomal dominant heredity (Table 2). Very few families 
with hereditary PC only have been reported. Ten years ago the relevance of the "10% rule" in 
PC was questioned (Proye et al 1994), since long follow-up resulted in detection of more 
cases with hereditary PC/PG. 
Table 2: Syndromes associated with familial PC/PG 
Syndrome Gene Function Chromosome Overall incidence of PC (%) 
MEN 2 RET Tumour proto-oncogene lOqll 30-50 
VHL VHL Tumour suppressor 3p25 15-20 
VRD NF1 Tumour suppressor 17ql 1 1-5 
Hereditary PG SDHD Tumour suppressor 11q21-23 ... 
Recently it was reported that almost one fourth of the patients with apparently sporadic PC in 
fact had mutations in RET, VHL, NF1 or SDHD at screening (Table 2) (Neumann et al 2002, 
Bryant et al 2003). Genetic testing as a routine was therefore proposed for patients with 
sporadic PC. 
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4.3.4 Criteria for malignancy. Several investigators have reported that longer follow-up of 
patients with PC/PG result in higher number of evidently malignant tumours, which exceed 
the historically cited "10%" (Pommier et al 1993, Proye et al 1994). Metastases may occur 
more than 10 yr after diagnosis and are common to regional lymph nodes, bones, liver, lung 
and brain (Vassilopoulou-Sellin 1998, Williams et al 2003). In recent series high numbers of 
malignant PC (>20%) have been reported (Kebebew et al 1998, John et al 1999). Many 
authors consider that the only reliable evidence of malignancy is the presence of metastases in 
an organ not normally containing chromaffin tissue, since the histopathological evaluation 
cannot reliably distinguish between malignant and benign tumours (Pommier et al 1993, 
Clarke et al 1998, Kubota et al 1998, Goldstein et al 1999, Edström et al 2003). Criteria for 
malignant PC/PG have been suggested by the Armed Forces Institute of Pathology; presence 
of metastases and/or extensive local invasion (Lack 1997). Microscopic features like local 
invasiveness of blood vessels or tumour capsule, and increased mitotic rate, are usually signs 
of malignancy in other tumour types, but may occur in both malignant and benign PC (van 
Heerden et al 1990). 
4.3.5 Preoperative management. Induction of anaesthesia and surgical resection of PC 
without prior a-adrenoceptor blockade has been associated with high mortality (24-50%). 
During surgery these patients can have circulating CA levels up to 500 times higher than 
normal (Russell et al 1998). Thus, patients with PC are recommended a-adrenoceptor 
blockade prior to any intervention to decrease the risk for hypertensive crisis (Russell et al 
1998, McClellan 2002). The most commonly used drug is phenoxybenzamine (pbz), which is 
a non-selective and non-competitive a-receptor antagonist with long-lasting effect (McClellan 
2002). Use of pbz has decreased the intra-operative mortality to very low figures (2%) (Grant 
1997). It u sually takes up to 2 wk to obtain adequate blockade and control of hypertension 
(Russell et al 1998, McClellan 2002). The non-selective action of pbz affects 0C2-
adrenoceptors in addition to ai-adrenoceptors and may cause loss of feedback inhibition via 
cardiac sympathetic nerves in turn leading to tachycardia, which may require additional 
blockade of ß-adrenoceptors. The use of ß-blockade before a-receptor blockade can worsen 
hypertension secondary to unopposed vasoconstriction (McClellan 2002). Other treatment 
alternatives include selective oti-blockade, calcium channel antagonists and metyrosin (Proye 
et al 1989, McClellan 2002). 
4.3.6 Surgical treatment. Surgery is a standard treatment of benign PC w ith low operative 
mortality (<3%), if the patients are properly prepared (NCI 2003, Williams et al 2003). 
Laparoscopic removal has become the first option at most centres today with low morbidity 
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and short hospital stay. In patients with familial, or bilateral, PC cortical-sparing adrenal 
resection has been recommended to avoid long-term steroid substitution (Williams et al 
2003). Prophylactic contralateral adrenalectomy is not recommended in familial PC with 
diagnosed unilateral tu mour (Inabnet et al 2000, NCI 2003). In malig nant PC with regional 
lymph node metastases, or in systemic tumour disease, an active surgical approach has been 
recommended as an attempt to increase survival (Mahoney et al 1977, NCI 2003). 
4.3.7 Cytotoxic agents and MIBG radiotherapy in malignant PC. In non-resectable PC 
radiotherapy with 131I-MIBG and chemotherapy can be considered in addition to medical 
treatment of CA hypersecretion/hypertension (Grant 1997, NCI 2003). MIBG radiotherapy 
has had limited success due to low uptake of radioisotope in the tumour, but may increase 
survival in selecte d cases (Grant 1997, Loh et al 1997, NCI 2003). Chemotherapy with the 
triplet CVD [Cyclophosphamide + Vincristine + Dacarbazine] (cf. Averbuch et al 1988) has 
resulted in object ive tumour regression (61%) and biochemical response (74%), but th ere is 
no evidence that it will improve survival (NCI 2003). Combination of MIBG radiotherapy and 
CVD treatment may have additive effects (Sisson et al 1999). External radiation can be used 
as palliative treatment of bone metastases (Grant 1997). 
4.3.8 Clinical outcome and cause of death. Several studies have reported an increased risk 
for unexpected death in patients with PC due to high CA secretion (Kebebew et al 1998, 
Russell et al 1998). Cardiovascular arrest was the main cause of death in patients with non­
diagnosed PC (Kebebew et al 1998, Lo et al 2000). Few series have analysed the late cause of 
death in patients with diagnosed and treated PC (Williams et al 2003); the causes were 
considered to be cardiovascular disease and recurrent tumour (Kebebew et al 1998, Lo et al 
2000). In these series, the follow-up was too short and often limited by small numbers of 
patients. 
There is no large consecutive series with long follow-up that has evaluated the total risk 
and the cause of death in patients with surgically treated PC/PG. To avoid selection biases 
the results in regional series should be compared with national cohorts. 
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5. Aims 
1. To evaluate our treatment strategy for ACC including active surgical treatment of 
primary/recurrent disease monitored treatment with mitotane in an adjuvant setting 
and determination of urinary steroid profiles to detect early recurrence (I). 
2. To review the literature in order to find the best medical treatment for recurrent/non-
resectable ACC, which can serve as background for discussion of future randomized 
studies (II) 
3. To find new markers of malignancy in adrenal medullary and cortical tumours by 
evaluating immunocytochemical expression of CAM in relation to clinical behaviour 
(III). 
4. To identify risk factors and causes of death in patients with PC/PG by studying the 
long-term survival and outcome after surgery in a large regional consecutive series of 
patients (1950-1997) (IV). 
5. To evaluate the death risk and occurrence of second tumour disease in a national 
cohort of clinically diagnosed PC (1958-1997) (V). 
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6. Patients and methods 
6.1 Adrenocortical carcinoma (I, II) 
Patients. Eighteen consecutive patients with a mean age of 53 + 3 yr and a female/male ratio 
of 0.8 were studied up to 1997. Complete resection was performed in 17 out of 18 patients. 
Palliative debulking surgery was performed in one patient. Seventeen patients were primary 
cases and one was referred after primary surgery elsewhere. Fourteen patients were offered 
monitored mitotane as adjuvant therapy; 12 patients (6 Stage II, 2 Stage III and 4 Stage IV) 
accepted such treatment. Two years later 4 more patients were included (12 Stage II, 2 Stage 
III, 8 Stage IV), all treated with mitotane. In 2002 the series included 30 patients (13 Stage II, 
5 Stage III and 12 Stage IV). Tumour staging at the time of primary surgery was based on the 
McFarlane/Sullivan classification. The survival was calculated with the Kaplan-Meier 
method. Correlation between disease-free interval and observed survival after repeat surgery 
was calculated as Pearson's coefficient. All p-values were two-tailed. 
Methods (I). Postoperatively, all patients were followed at 3 m intervals during the first year 
with clinical examination and urinary steroid profiles. CT/MRI was performed at 6 mos. 
intervals. Patients with no evidence of disease were thereafter followed every 6 mos. The 
mitotane dose was titrated by monitoring of serum levels every 1-2 wk during the first 2-3 
mos. of treatment and later every 3 mos., or earlier on suspicion of side effects. The serum 
concentration of mitotane was measured by capillary gas chromatography with an electron 
capture detector (ECD) (Moolenaar et al 1977, Benecke et al 1987) and was adjusted to the 
so-called "therapeutic interval" (14-20 (xg/ml) (van Slooten et al 1984). Patients with 
advanced disease received mitotane life-long, while patients without evident disease were 
planned for a treatment period of 3 yr. Since 1990 urinary steroid profiles were regularly 
performed at our hospital; 12 patients had postoperative samples and five patients had 
preoperative samples as well. The steroids were extracted before enzyme hydrolysis of steroid 
conjugates as methoxine-trimethylsilyl derivatives and analysed by gas chromatography/mass 
spectrometry (Axelsson et al 1981, Schmidt et al 1985). 
Methods (II). A detailed review of the world literature on available medicai treatment for 
advanced ACC (metastatic or recurrent) was performed including symptomatic endocrine 
therapy, mitotane, single/multiple agent chemotherapy as basis for future trials. 
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6.2 Expression of cell adhesion molecules in adrenal tumours (III) 
Tumours. Eighty-seven adrenal tumours were investigated by immunocytochemistry and/or 
Western blotting (WB). Fifty-seven benign adrenal tumours (27 PC and 30 ACA) were 
randomly selected among specimens registered at the Department of Pathology, Sahlgrenska 
University Hospital (1965-1999). All malignant adrenal tumours (8 sporadic malignant PC 
and 22 ACC) (1979-1999) were also included. Fresh tumour tissues (10 sporadic benign PC, 
10 ACA and 10 ACC) were obtained from 30 of the patients and were analysed by WB. 
Methods, a) Immunocytochemistry. Sections of formalin-fixed and paraffin embedded 
material were mounted on positively charged glass slides, deparaffinized, rehydrated and 
subjected to antigen retrieval by microwave treatment. Primary antibody was applied 
overnight at 4°C. Bound antibodies were visualized by indirect immunoperoxidase techniques 
(DAKO EnVision +). All slides were coded and evaluated by three independent observers. 
The following monoclonal antibodies were used; anti-tyrosine hydroxylase (TH) (2/40/15), 
anti-CD44 (A3D8), anti-ECAD (HECD-1), anti-NCAD (3B9), anti-NCAM (ERIC-1), and 
anti-Ki-67 (MIB-1). As positive controls served for TH: normal adrenal medulla, CD44: 
haematopoietic tissue, ECAD: intestinal mucosa, NCAM, NCAD: normal adrenal gland, 
Ki67: lymph node. In negative controls the primary antibody was omitted. The number of Ki-
67 positive nuclei and mitotic figures were counted in 10 high power fields from each tumour, 
b) Western blotting. Frozen tumour tissues were homogenized in 10 mM potassium-
phosphate buffer pH 6.8 containing 1 mM EDTA, 10 mM 3-(3-cholamidopropyl) 
dimethylamonio-1 -propane sulphate and protease inhibitors. Homogenates were sonicated 
twice for 15 sec followed by centrifugation for 10 min at 10,000 g. The clear supernatant was 
withdrawn, assayed for protein content according to Bradford, and stored at -80 °C. Aliquots 
of proteins (20-35 |ig protein) were diluted in sample buffer. Reducing agents was added 
followed by denaturation at 70 °C for 10 min and electrophoresis on precast Polyacrylamide 
gels (10% NuPAGE Bis-Tris-gels; Novex) using NuPAGE MOPS SDS as running buffer. 
Proteins were transferred to polyvinyldifluoride membranes using a Novex blotting system. 
Membranes were incubated with primary antibodies at 4 °C over night followed by alkaline-
phosphatase-conjugated goat-anti-rabbit/mouse antibody and CDP-Star (Tropix) as substrate. 
Membranes were exposed to ECL film at room temperature for 10-120 sec. Molecular weight 
markers (See-Blue or Mark 12, Novex) were used to calculate the apparent size of 
immunoreactive proteins. 
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6.3 Pheochromocytoma and paraganglioma (IV, V) 
Patients. Regional series (IV). A total of 121 consecutive patients with PC/PG (68 females 
and 53 males, median age at surgery: 47 yr, range 15-82 yr were operated at our unit (1950-
1997). Hypertension was defined according to the WHO recommendation >140/90 mm Hg 
{Chalmers 1999). 
Patients. National cohort (V). All patients (n=660) with diagnosed adrenal PC during 1958-
1997 in Sweden, registered in the National Cancer Registry (NCR) were identified. Autopsy-
based diagnoses (n=179) were excluded and a cohort of 481 patients with clinically diagnosed 
tumours was included in the analysis. 
Methods. Regional series (IV). a) Archival data. Clinical and biochemical data, tumour 
characteristics and localization, as well as anaesthesiological and surgical procedures were all 
obtained from the medical records. The mean value of the 3-5 highest blood pressure 
recordings before and within one year after surgery was calculated in available patients 
(n=116). The concentrations of adrenaline (A), noradrenaline (NA), methoxy-CA and VMA 
were analysed in 24 h urine collections; the mean of the 3-5 highest preoperative levels was 
recorded. All patients alive in 1980, and all successive patients, were biochemically screened 
for multiple endocrine neoplasia type 2 (MEN 2) with analyses of basal and pentagastrin-
stimulated serum calcitonin concentrations after adrenal surgery. Genetic testing has been 
routine for all patients with medullary thyroid cancer (MTC) since 1995. 
Early in the series, the tumours were localized by angiography and in individual patients by 
pneumoperitoneum. These techniques were after 1981 replaced by CT. Scintigraphy, using 
radioiodinated MIBG, was used alone or in combination with CT after 1985. One hundred 
twelve patients were treated with pbz preoperatively; an initial dose of 10-40 mg/d was given 
orally, increased by 10-20 mg/d at intervals of 1-3 d until symptomatic relief and control of 
hypertension was achieved. The individual final dosage varied largely (20-400 mg/d). The 
anaesthetic records of 77 patients (1960-1997) were carefully evaluated concerning intra­
operative blood pressure variations and other complications. 
Histopathologically malignant diagnosis was based on presence of extensive local invasion, or 
on detection of metastases to one or more sites, where chromaffin tissue is not usually present 
(cf. Lack 1997). Tumours with features as irregular growth pattern, areas of necrosis, local 
invasiveness of blood vessels or tumour capsule, cellular polymorphism, and increased 
mitotic rate, were recorded separately as a "border-line risk" group. In 4 patients diagnosis of 
adrenal medullary hyperplasia data was confirmed by morphometric analysis to assess adrenal 
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medullary weight and volume (Jansson et a/ 1988). All patients alive in 1997 (n=79) were 
subjected to follow-up. For deceased patients, the cause of death was obtained from death 
certificates, autopsy reports, or medical records. 
b) Statistics. Statistical analyses were performed to evaluate clinically relevant factors for 
survival and malignant disease. The relationship between age at surgery, sex, recognized 
hereditary disease, associated cardiovascular and tumour diseases, presenting symptoms and 
their duration, blood pressure pre- and postoperatively, urinary levels of CA and metabolites, 
tumour weight and the risk for death were tested by a non-parametric test (Breslow et al 
1987). The expected number of deaths was calculated, assuming that the risk coincided with 
that of the general Swedish population taking age, sex and calendar year into account and 
compared with the observed numbers of deaths (Poisson distribution) using two-tailed tests. 
Methods. National cohort (V). a) Registry data. Since 1958 the Swedish National Board of 
Health and Welfare requires that all clinicians and pathologists/cytologists report all clinically 
and autopsy-diagnosed malignant and several benign tumours. Consequently, the cases 
included in NCR are reported from two sources, but the registry does not contain any 
information on tumour Stage or treatment. The completeness of the registry is approximately 
98% (Lundegårdh et al 1990, Hansson et al 1999). To maintain confidentiality each 
individual is given a code number, which is also used in the National Registry of Deaths & 
Main Causes of Death. This registry reports the total number of deaths and the number of 
deaths from different causes separately for men and women in 5-year age cohorts. The data in 
these registries can be cross-matched, so no one can be included in a series more than once. 
The following information was obtained from the registries; diagnosis based on the diagnose 
number for PC (195.0) listed according to 1CD-7 ( WHO 1957), sex and age, date of diagnosis, 
diagnostic modality (histopathology/cytology), histopathologically verified malignancy, cause 
of death based on the ICD-7 death code, but also each new tumour disease after diagnosis of 
PC. The control population was the entire Swedish population (~ 8.2 millions). The observed 
numbers of death and causes of death in patients with PC were compared with the expected 
numbers in the control population. The incidence of additional tumour diseases (metastases 
not included) in patients after diagnosis of adrenal PC were analysed in NCR and compared 
with that of the control group. 
b) Statistics. The expected numbers of deaths and new tumour diseases after diagnosis of 
adrenal PC were calculated taking current age, sex and calendar year into account. The patient 
years related to different age intervals, sex and time were multiplied by the corresponding risk 
25 
figures of the normal population and the products were added. The observed and expected 
numbers were compared by use of the Poisson distribution. Confidence intervals for risk 
ratios were calculated exactly. Analyses were performed for men and women separately. 
Two-tailed tests were used. 
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7. Results and Discussion 
7.1 Adrenocortical carcinoma (I, II) 
7.1.1 Clinical features. The most common clinical manifestations of ACC in our patients 
were fatigue, abdominal pain, and abdominal mass. One-third of patients had hormonal 
symptoms. 
7.1.2 Surgery. All 22 patients (12 Stage II, 2 Stage III, 8 Stage IV) underwent 
macroscopically radical surgery by adrenalectomy alone or combined with nephrectomy, or 
more extensive surgery (Figure 4). There was no postoperative mortality. Re-exploration was 
performed in 9 patients; in 5 patients due to biochemical suspicion of recurrence after a mean 
disease-free interval of 59 mos. Four patients underwent second-look operation without signs 
of recurrent disease. The outcome for the 5 re-operated patients was as following: Two died 
of ACC (Stage II & IV), one died of other causes (Stage II), one was alive with disease (Stage 
II), an d one patient had no evidence of disease (Stage II). Th e mean observed survival after 
repeat surgery was 55 mos. 
Figure 4: 5-year survival of 22 consecutive patients with ACC (1971-1999) 
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7.1.3 Mitotane therapy. After titrating mitotane to a median serum concentration of 14.5 
|ig/ml (range 13-20 ng/ml) the median daily dose was 4 g (range 2.0-6.5 g). Significant side 
effects were reported in 5 out of 12 patients; one (Stage II) refused further mitotane treatment 
after negative second-look operation. Four patients had nausea and one had visual 
disturbances; all could continue after dose reduction. Two elderly patients refused mitotane 
initially due to potential side effects. Figure 5 shows dose adjustment in a patient with nausea 
during induction with mitotane. 
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Figure 5: Dose and serum concentration of mitotane in a patient with nausea during 
induction of mitotane therapy. 
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With a daily dose of 6.5 g of mitotane nausea appeared and the dose had to be reduced. In this patient it to ok 
about 20 wk to reach a stable scrum concentration of mitotane with a dose not causing any side effects (around 
14 ng/ml). In most patients 2-3 mos. of treatment was needed to reach such individual dosage. 
7.1.4 Additional therapies. Five patients received additional treatment; radiation therapy 
(n=l), streptozocin alone (n=4) or combined with doxorubicin (n=l), or interferon (n=l), or 
chemoembolization of the liver with doxorubicin (n=l), when the initial treatment with 
surgery and mitotane had failed. Two patients with Stage II disease received streptozocin at 
tumour recurrence; one died 24 yr after surgery with no evidence of disease, the other patient 
died of ACC 6 yr after surgery. The third patient, treated with streptozocin, had Stage IV 
disease and died of ACC within 8 mos. The fourth patient also had Stage IV disease treated 
with streptozocin combined with interferon died of ACC within 4 mos. The fifth patient also 
with Stage IV disease received a combination of doxorubicin and radiation and died of 
disease 3.5 yr after initial surgery. 
7.1.5 Urinary steroid profiles. Patients without recurrent disease had steroid profiles 
identical with the first postoperative urine collection. One female patient with Stage II tumour 
and virilism developed a selective increase of the secretion of pregnanediol, pregnanetriol, 
and androstentriol, which led to second-look operation with normal findings. In subsequent 
urinary profiles these steroids were again normalized. To date this patient (11 yr) is still alive 
with no evidence of disease. In two out of 5 patients with pre and postoperative urine samples 
the steroid profiles indicated recurrent disease despite normal radiological findings. One 
patient had normal radiological findings, but high secretion of 3-ß-hydroxy-5-ene steroids, 
which increased rapidly. The patient died of disseminated disease 4 mos. later. Another 
patient rapidly recurred with a steroid pattern typical for the original tumour. She was re-
operated 6 mos. later, when she had developed radiologically proven liver metastases. 
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Another patient clearly had a pathological steroid profile preoperatively (Figure 6). The 
primary tumour was excised, but she had residual tumour in the liver. The steroid profile after 
surgery showed diminished secretion of androgens (androsterone, etiocholanolone, DHEA 
and 11-OH androsterone), but persistent secretion of pregnanediol & -triol, pregnenediol & -
triol and glucocorticoids (tetrahydrocortisone/cortisol, cortolon and cortoles), suggesting that 
the primary tumour was the source of androgen production. 
Figure 6: Pre- and postoperative urinary steroid profiles in a patient with ACC, Stage IV. 
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7.1.6 Survival. The 5-year survival according to the Kaplan-Meier method was for the 18 
patients in paper I was 58%. The median observation time for the 8 patients, who died of 
ACC was 0.5 yr (range 2-72 mos) and for the other 10 patients 7.2 yr (range 7-294 mos.). The 
5 patients with repeat surgery for recurrent disease after a mean disease-free interval of 59 
mos. (7-168 mos.) survived for a mean of 55 mos. (2-120 mos.) after the second operation. 
There was a significant correlation between disease-free interval before and observed survival 
after repeat surgery (p = 0.014). 
7.1.7 Treatment alternatives in advanced disease (II) 
a) Inhibitors of steroid biosynthesis. Control of hormonal symptoms can cause good 
palliation. Metyrapone blocks the 11 ß-hydroxylation of the Cortisol synthesis (cf. Figure 1), 
but can enhance androgen synthesis (hirsutism and virilism). It is an effective second-line 
drug for all types of Cushing's syndrome with reversible effects (Trainer et al 1994). 
Ketoconazole inhibits both gonadal and adrenal steroid synthesis by its action on 11 ß-
hydroxylase and 18-hydroxylase and the cholesterol synthesis (cf. Figure 1). Hepatotoxicity is 
a serious side effect. It is particularly effectiv e in the treatment of hypercortisolism caused by 
ACC and may have antiproliferative effects (Feldman 1986). Aminoglutethimide blocks the 
conversion of cholesterol to pregnenolone by inhibition of aromatases in all tissues (cf. Figure 
1) and therefore reduces the synthesis of Cortisol, aldosterone and estrogens (Trainer et al 
1994). 
b) Glucocorticoid receptor antagonist. RU 486 (mifepristone) is a potent glucocorticoid 
receptor antagonist, which can be effective in the treatment of Cushing's syndrome. One 
obvious limitation for monitoring of clinical response is that Cortisol levels are not lowered 
and hypocortisolism not easily identified (Bertagna et al 1988). 
c) Chemotherapy with single agent. Suramin had low response rate (14%) and serious side 
effects, so this treatment has been abandoned (Arlt et al 1994). Gossypol could induce partial 
remission, but only in a minority of patients with metastatic ACC (Flack et al 1993). 
Doxorubicin: In a prospective non-randomized study of advanced ACC patients with 
functional, well- or poorly differentiated tumours (n=36), who first received mitotane (6g/d) 
for 3 mos. had better response rate (22%) than those, who only received doxorubicin (19%) 
(Decker et al 1991). Patients with progressive disease on mitotane were crossed-over to 
doxorubicin without any objective response. Doxorubicin thus seemed to be ineffective as 
second-line chemotherapy for patients with functional ACC. Cisplatin: Initially individual 
transient complete responses with cisplatin (Chun et al 1983) and an improved response rate 
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with cisplatin and mitotane were reported (Bukowski et al 1993). These results were not 
corroborated by later studies ( Williamson et al 2000). 
d) Chemotherapy with multiple agents. Before 1998 the results with chemotherapy using 
multiple agents were not encouraging, but this year a combination of cisplatin, etoposide and 
mitotane (mEP) was reported to offer a response rate of 33% (Bonacci et al 1998) (Table 4). 
Table 4: Combined chemotherapy in ACC 
Series Number Regimen Year Response rate 
van Slooten 11 PDC 1983 18% 
Schlumberger 13 DP5-FU 1991 23% 
Bukowski 37 mP 1993 30% 
Bonacci 18 mEP 1998 33% 
Berruti 28 mEDP 1998 54% 
Williamson 45 mEC 2000 11% 
Khan 22 mS 2000 36% 
Abraham 36 mEDV 2002 22% 
B - bleomycin C = cyclophosphamide D = doxorubicin E = etoposide m = mitotane 
P = cisplatin, S = streptozotocin V = vincristine 5-FU = 5-fluorouracil 
In a phase II multicenter trial EDP treatment was combined with mitotane (mEDP) (Berruti et 
al 1998). The overall response rate among the 28 patients (both functioning and non­
functioning advanced ACC) with measurable disease was high (54%). The time to 
progression in responding patients was two years. EDP treatment was reasonably well 
tolerated and only few patients needed reduced doses, or discontinued their therapy. The 
addition of mitotane increased the side effects leading to reduction of the planned mitotane 
dose (4 g daily) in a majority of patients. All patients were substituted with hydrocortisone 
combined with mineral corticoids. 
7.1.8 Comments. In our region treatment of ACC is centralized to our centre and all patients 
in this limited series were consecutive cases from the Western Region of Sweden; the 
selection bias may include non-resectable Stage IV disease and ACC not clinically diagnosed. 
Complete tumour removal was possible in 17 out of 18 patients (50% Stage II and 50% Stage 
III-IV). Patients with Stage II disease had good prognosis. Second-look operations in such 
patients without any biochemical or radiological evidence of recurrence can today be avoided 
with more reliable radiological investigations. At the end of our study the 8 deceased patients 
only survived for a mean of 0.5 yr after surgery, whereas the survivors (9 Stage II, 1 Stage III 
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and 2 Stage IV) were observed for a mean of 7.2 yr. The mean survival time before repeat 
surgery for recurrence in the 5 reoperated patients was almost 5 yr and so was the observed 
survival after the second operation. In accordance with previous studies the significant 
correlation between disease-free interval and long survival after the repeat surgery suggests a 
survival advantage for these patients. 
Analysis of urinary steroid profiles in our series enabled early detection of recurrence in two 
patients, but both patients were reluctant to re-exploration without radiological evidence of 
disease. After completion of this study another two patients developed steroid profiles 
compatible with tumour recurrence, which led to rapid medical treatment. One patient had a 
false positive finding and was explored with negative results. Thus, the urinary steroid profile 
may be a tool for early detection of recurrent disease in individual patients. Previous studies 
have proposed that patients with ACC may have specific patterns in their urinary steroid 
profiles, which could discriminate malignant from benign cortical tumours (Minowada et al 
1985, Gröndal et al 1990). It has recently reported that patients with ACC had a dominance of 
11-deoxycortisol or 3ß-hydroxy-5-ene steroids vs. Cor tisol, 18-hydroxycortisol, or aldosterone 
in patients with ACA (Kikuchi et al 2000). Since the individual secretory pattern can vary 
depending on age, sex and hormonal status (e.g. pregnancy, menstrual cycle), a steroid profile 
(determined by gas chromatography/mass spectrometry) diagnostic for ACC, based on 
numerical figures of certain key steroids, cannot be given at present time (cf. Weykamp et al 
1989). 
All our patients treated with mitotane had their treatment adjusted after the serum 
concentrations of the drug. This strategy enabled long-term treatment in the majority of our 
patients with rather few side effects. Due to the small number of patients and a treatment 
period without mitotane monitoring, no conclusion about the efficacy of mitotane treatment 
can be drawn. However, in a large retrospective series (n=253) from France mitotane 
treatment seemed to offer a survival advantage in patients with metastatic ACC or with 
residual tumours, i.e. high Stage or non-resectable disease (Icard et al 2001). In our series 8 
Stage IV patients were included; 4 with and 4 without mitotane treatment with a 5-year 
survival of 50% vs. 0%. 
We reviewed the literature to find better medical treatment for patients with advanced/non-
resectable ACC, which also could serve as a background for future randomized studies. With 
our present knowledge single agent chemotherapy is not effective; the best results were 
obtained by multiple agent therapy, but such therapy without addition of mitotane was not 
very successful (Table 5). The patients in these series were few and the response rates low 
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{van Slooten et al 1983, Schlumberger et al 1991). Since mitotane partially reverses the 
"MDR-1" multi-drug resistance gene by reducing drug efflux, combined treatment with 
mitotane and cytotoxic agents seems to be theoretically favourable {Bates et al 1991). 
Bonacci et al {1998) treated 18 patients with cisplatin and etoposide combined with mitotane 
(mEP) and reported 33% response rate. In a phase II multicenter trial EDP treatment 
combined with mitotane (mEDP) had a response rate of 54% {Berruti et al 1998). EDP has 
been widely used in gastric carcinoma and has been accompanied by significant side effects 
and toxicity-related deaths. However, in ACC patients it was better tolerated, which can be 
due to lower dosage of etoposide and better performance status of the ACC patients. The 
combination of mitotane and streptozocin (mS) has been used with variable results {Gröndal 
et al 1990, Haak et al 1994). However, a recent study showed a response rate of 36% with 
significant effect on disease-free interval and survival {Khan et al 2000). Thus, mitotane-
based chemotherapy with mEDP and mS both had response rates higher than 30%. A 
randomized, multicenter trial comparing these treatment arms in advanced ACC will soon be 
launched using monitored mitotane therapy {Schteingart, pers. comm.). 
Table 5: The results of reoperation in some recent series ofpatients with ACC 
Stage Stage Primary 5-y Survival 5-y Survival after 
Author Patients I& III & Complete Recurrence after complete non-complete re-
No. II IV resection No. re-resection resection 
Icard 156 53% 47% 81% 22 28% (n=12) 8% 
(1992) 
Bellantone 170 51% 49% 80% 52 50% (n=20) 8% 
(1997) 
Schulick 113 50% 50% 60% 47 57% (n=32) 0% 
(1999) 
ACC is a heterogeneous disease; some patients with resected metastatic disease survive for 
long periods, while others die within months from rapidly progressive disease, poorly 
responsive to medical therapy. The tumour biology in individual patients can be difficult to 
predict {Vassilopoulou-Sellin et al 2001). Intentionally curative surgery increases the 5-year 
survival in Stage I-III disease {Kendrick et al 2001), but even after complete resection a 
majority of ACC patients will develop recurrences {Icard et al 1992, Pommier et al 1992, 
Bellatone et al 1997). The surgical attitude to treat recurrent tumour varies largely between 
different series. Table 5 shows the results of repeat surgery in recurrent disease. 
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Due to the high risk for recurrent disease in ACC adjuvant medical treatment of both low and 
high Stage tumours has been tested. Adjuvant use of mitotane is still controversial, mainly 
due to the lack of randomized prospective studies of sufficient size. Another obstacle for 
treatment is the severe side effects of mitotane. Retrospective studies of mitotane serum levels 
vs. clinical outcome have indicated that drug concentrations >14 Jig/ml are required for 
therapeutic responses (van Slooten et al 1984). Mitotane is a lipophilic substance with large 
inter-individual variation between dosage and serum levels of the drug. Side effects are 
frequent with drug levels close to 20 jig/ml. Monitoring of mitotane levels at institution of 
this therapy improves the quality of life for the patients and prevents toxic drug levels (van 
Slooten et al 1984, Terzolo et al 2000). There is no consensus about the duration of adjuvant 
mitotane treatment, but 2-3 yr may be reasonable time with a toxic drug in patients without 
recurrence. The effect on sex steroid secretion and its reversibility has not been sufficiently 
studied. The overall survival in our consecutive series updated to 30 patients in 2002 (44% 
low Stage and 56% high Stage tumours) compares favourably with the best reported; the 
overall 5-year survival was 65%, Stage II 74% and Stage III & IV 58% (Figure 7). 
Figure 7: 5-year survival of 30 consecutive patients with ACC (1975-2002). 
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If the one, or several, components in our treatment strategy (active surgery, adjuvant 
monitored mitotane therapy and urinary steroid profiles during follow-up) contributed to the 
treatment results cannot be assessed. 
7.2 Cell adhesion molecules in adrenal tumours (III) 
7.2.1 Results, a) NCAD. Immunocytochemical expression of NCAD was shown in the 
normal adrenal cortex and medulla with labelling confined to cell membranes of cortical 
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parenchymal cells and medullary chromaffin cells. It was strong in all layers of the adrenal 
cortex, but much weaker in the medulla. All adrenal tumours expressed NCAD, but to 
different degrees (Table 6). The labelling was confined strictly to the cell membranes of 
tumour cells with no staining over stroma, blood vessels or lymphocytes (Figure 8). WB 
demonstrated a single immunoreactive band of approximately 100 kDa in almost all benign 
PC and AC A, but only in 5 out of 10 ACC in accordance with the immunocytochemical 
results (Figure 9). 
Table 6: Summary of immunocytochemical findings in adrenal tumours 
TH CD 44 NCAD ECAD NCAM Ki-67 index 
BPC 27/27 23/27 12/27 0/27 26/27 8±12 (1) 
(n = 27) (0/0/0/27) (4/6/1/16) (15/4/6/2) (27/0/0/0) (1/2/8/16) 
MPC 8/8 6/8 8/8 0/8 7/8 14+24(1) 
(n = 8) (0/0/0/8) (2/0/1/5) (0/3/1/4) (8/0/0/0) (1/0/1/6) 
ACA 0/30 7/30 28/30 0/30 21/30 11±13 (1) 
Ol = 30) (30/0/0/0) (23/6/1/0) (2/5/6/17) (30/0/0/0) (9/4/8/9) 
ACC 0/22 4/22 9/22 2/22 17/22 370+780(4) 
(n = 22) (22/0/0/0) (18/1/2/1) (13/5/3/1) (20/2/0/0) (5/4/7/6) 
The results of analysis for TH, CD44, NCAD, ECAD and NCAM expression are given as the number of positive 
tumours/total number of tumours. The number of positive cells was graded as follows: 0 = no labelled tumour 
cells, + = 1-24% positive cells, ++ = 25-74% positive cells, +++ = >75% positive cells. The estimated 
percentage of labelled cells in positive tumours is given within brackets (0, +, ++, +++). For Ki67, the number of 
positive nuclei in 10 high power fields (HPF) is given as mean + SD. The number of mitotic figures per 10 high 
power fields is given within brackets. (BPC: Benign PC, MPC: Malignant PC, ACA: Adrenocortical adenoma, 
ACC: Adrenocortical carcinoma). 
b) ECAD. There was no ECAD staining in the normal adrenal cortex or medulla, neither was 
it expressed in the adrenal tumours (Figure 8). WB did not reveal ECAD in any of the 
investigated cortical/medullary tumours (Figure 9). 
c) NCAM. NCAM was demonstrated immunocytochemically in the normal adrenal cortex 
and medulla with labelling confined to cell membranes of cortical parenchymal cells and 
chromaffin cells; it was stronger in the medulla. All adrenal tumours expressed NCAM, but to 
different degrees (Table 6). The labelling was mainly distributed over cell membranes of 
tumour cells (Figure 8). WB demonstrated two immunoreactive bands at 180 kDa and 150 
kDa, respectively, in the majority of benign PC, ACA, and ACC (Figure 9) in accordance 
with the immunocytochemical results. 
d) CD44. Focal and weak labelling of CD44 was demonstrated in cell membranes of cortical 
cells (zona glomerulosa) and strong labelling in the cell membrane of chromaffin cells of the 
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medulla. All adrenal tumours expressed CD44 (Table 6). All PC had strong membranous 
staining and the cortical tumours very weak cytoplasmic staining (Figure 8). WB 
demonstrated a single immunoreactive band of approximately 65 kDa in 10/10 benign PC, 
9/10 ACA, and 6/10 ACC (Figure 9). 
Figure 8: Expression of CAM in adrenal tumours demonstrated by immunocytochemistry 
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Immunocytochemical demonstration of CAM in primary adrenal tumours. NCAD, NCAM and CD44 were 
expressed in all types of adrenal tumours, usually with a distinct membrane labelling. ECAD was only detected 
in very few ACC with a patchy, cytoplasmic labelling. (PC: Pheochromocytoma, MPC: Malignant PC, ACC: 
Adrenocortical carcinoma, ACA: Adrenocortical adenoma) 
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e) Ki-67. The number of Ki-67 positive tumour cells was low for PC and ACA, whereas ACC 
had very high Ki-67 index (Table 6). 
0 TH. In the cy toplasm of all chromaffin cells of the medulla TH was demonstrated, but not 
in cortical parenchymal cells. All PC (benign and malignant) demonstrated strong 
cytoplasmic staining for TH, but no staining for TH was seen in cortical tumours. 
Figure 9: Expression of CAM in adrenal tumours demonstrated by Western blotting (WB) 
re ACA ACC 
NCAD 
- 191 
- «4 köa 
«*51 kl>» 
- 3» feIX» 
PC ACA ACC 
t 3 i 4 S » 1 « » Ml tt « 
flftMKgHHi J 
NC AM 
- 1*1 fclJht 
- M «s»* 
- »1 k fia 
- 39 kD» 
Western blotting demonstrating 
CAM in adrenal tumours. A 
single NCAD-band of 
approximately 100 kDa was 
detected in all sporadic BPC, a 
majority of ACA and in half of 
the ACC. NCAM was 
demonstrated as two 
immunoreactive bands of 
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and ACC. A single CD44 band 
of approximately 65 kDa was 
demonstrated in all sporadic 
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half of the ACC. 
»H ACA ACC 
) ••••t  11 •> 
S J J 4 S «. 7 » » S« 1 » 82 
C »44 ::g 
191 kl>a 
«4 kH ii 
51 fcl)» 
39 Mh> 
7.2.2 Comments: The expression of CAM has been evaluated extensively in m any tumour 
types, but adrenal tumours have not been studied in detail (Gupta et al 2000). The expression 
of adhesion molecules in different tumour types can be studied immunocytochemically on 
formalin-fixed paraffin sections. By using material from such archives with access to clinical 
data, information on prognosis can be obtained. The majority of PC in our series expressed 
CD44 (75-85%), but only 15-25% of the cortical tumours examined. CD44 is thus expressed 
in both tumour types, but with higher expression in medullary tumours. Barschack et al 
(1998) had suggested that CD44 might differentiate between medullary and cortical tumours, 
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but its importance as prognostic marker was not clear. Our data suggest that CD44 expression 
in adrenal tumours is not related to malignant course. NCAM was demonstrated in the normal 
adrenal gland and in the majority of cortical and medullary tumours. All layers of adrenal 
cortex express NCAM, but to different degrees. ACA and cortical hyperplasia had a 
membranous and ACC a cytoplasmatic staining (Zeromski et al 1998). Despite these 
differences, there was no evidence for loss of NCAM during adrenal tumorigenesis and no 
relation between its expression and the biological behaviour of cortical tumours. Loss of 
ECAD expression has been reported to be important for development of different tumours, 
e.g. breast cancer and endocrine pancreatic tumours (Perl et al 1998, Christofori et al 1999, 
Chen et al 2003, Kowalski et al 2003). ECAD was neither demonstrated in normal adrenal 
cortex or medulla, nor in adrenal tumours. Hence, there is no proof that ECAD is important 
for development of adrenal tumours and has no use as prognostic marker in adrenal tumours. 
NCAD expression varies in different tumours, but has been reported to be up-regulated in 
squamous cell carcinoma and breast cancer (expressed in one third of invasive breast 
carcinomas) (Kovacs et al 2003, Chen et al 2003, Ordonez 2003, Krengel et al 2004). NCAD 
was expressed in both cortical and medullary tumours regardless of their malignant potential. 
During cell transformation and tumour progression, NCAD expression was maintained in PC, 
but was down-regulated in ACC. The results suggest that NCAD may function as a tumour 
suppressor in adrenal cortical tumours. The reason why NCAD was not down-regulated in PC 
during development of malignant PC is unclear. We may assume that different malignant 
tumours have different expression patterns due to their biological characteristics and 
invasiveness. In order to maintain tissue dynamics, cell proliferation and programmed cell 
death (apoptosis) balance each other. It is important to study this balance to understand 
differences between normal, hyperplastic and neoplastic adrenal tumours (Sasano et al 1995). 
A higher cell proliferation, indicated by higher number of Ki-67 positive tumour cells, was 
reported for ACC than for ACA and normal cortex. A Ki-67 index >5% is suggestive for 
ACC (Nakazumi et al 1998, Wachenfeld et al 2001). For medullary tumours a Ki-67 index 
>3% had 50% sensitivity, but 100% specificity, to identify malignant PC (Clarke et al 1997). 
The Ki-67 index in our study discriminated between ACA and ACC. Studies using 
semiautomatic image analysis programs and large tumour cell populations from primary 
tumours have generated individual prognostic information for other endocrine tumour types, 
e.g. MTC (Tisell et al 2003). 
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7.3 Pheochromocytoma and paraganglioma (IV & V) 
7.3.1 Clinical features. Our consecutive series (1950-1997) consisted of 110 PC and 11 PG. 
Ninety-one patients had sporadic PC, 19 had PC as part of a MEN 2 syndrome and 11 patients 
had von Recklinghausen's disease (VRD). All PG were sporadic (Figure 10). The most 
frequent presenting symptom in patients with PC/PG was hypertension, equally common in 
benign and malignant tumours. The mean age at surgery for PC and PG was similar (47 + 22 
and 47 + 16 yr, respectively). There was a median delay of 12 m (range 0-360 m) between the 
occurrence of symptoms related to PC/PG and tumour diagnosis. The diagnostic delay was 
somewhat shorter (20 + 14 mos.) for malignant tumours vs. benign tumours (37 + 66 mos.). 
Figure 10: Review of 121 patients with PC/PG 
104 PC 9 PG 
All sporadic 6 PC 2 PG 
113 Benign tumours 8 Malignant tumours 
All sporadic 
74 Sporadic 19 MEN 2 
(15MEN2A, 4MEN2B) 
11 VRD 
121 pheochromocytoma (PC)/paraganglioma (PG) 
[68 F & 53 M, Median age at surgery 47 y. Follow-up; alive (n=79) 1997. Mean duration 16+11 y]. 
7.3.2 Hypertension. Hypertension was found in 98 out of 116 patients, in whom blood 
pressure was recorded at diagnosis. Less than half of the hypertensive patients had 
antihypertensive treatment before diagnosis. One year after surgery 100 patients had blood 
pressure recordings; two of the preoperatively normotensive patients (n=18) had developed 
hypertension and 57/100 patients with preoperative hypertension were still hypertensive. 
Thus, more than half of the hypertensive patients remained hypertensive after surgery. 
Notably, only one third of the hypertensive patients had received antihypertensive treatment 
postoperatively (Table 7). At latest follow-up in 1997, 66 out of 98 patients with initial 
hypertension were alive and 25 remained hypertensive (one third were on medical treatment). 
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The survival analysis showed that pre- or postoperative hypertension did not significantly 
influence the risk of death (p>0.30) vs. controls. 
Table 7; Blood pressure at diagnosis and during follow-up in patients with PC/PG 
121 PC/PG patients 
Blood pressure available (n=116) Blood pressure not available (n=5) 
Sporadic VRD MEN 2 Sporadic VRD MEN 2 
n= 87 n=ll n= 18 n= 4 n= 0 n= 1 
At diagnosis 
HP NP HP NP HP NP 
n=79 n=8 n=8 n=3 n=ll n=7 
One year postoperatively 
HP, n=46 HP, n=3 HP, n=8 Dead n=l 
16 mt 2 mt 1 mt No results available, n=10 
Blood pressure recordings before and within one year after PC/PG surgery. Out of 87 patients with sporadic 
tumours 79 were hypertensive at diagnosis. One year postoperatively 46 remained hypertensive; one 
normotensive had developed hypertension. Out of 11 VRD patients 8 were hypertensive at diagnosis; one year 
later 3 remained hypertensive. Out of 18 MEN 2 patients 11 were hypertensive at diagnosis; one year later 8 
patients were still hypertensive, (mt = mcdically treated). 
7.3.3 Hormonal diagnosis. Urinary analysis of VMA, NA, A, and methoxy-CA were 
performed in 104, 107, 97, and 70 patients, respectively. All malignant PC investigated (n=5) 
had elevated levels of methoxy-CA. At follow-up in 1997 one of the 60 tested patients had 
elevated urinary excretion of CA and metabolites. This patient had recurrent metastatic 
disease. 
7.3.4 Tumour imaging. One hundred and fourteen patients had imaging studies and in 4 
patients the tumours were not localized until surgery. No information was available for three 
patients. Between 1950 -1981, the most common imaging study was angiography with a 
positive diagnosis in 41 out of 46 investigated patients. In 7 patients pneumoperitoneum gave 
correct localization. From 1982 the tumours were localized by CT with a positive finding in 
55 out of 61 investigated patients. MRI was used as complementary study in 6 cases, in which 
CT had indicated tumour. In 42 patients MlBG-scintigraphy was performed with a diagnostic 
sensitivity of 79%. 
7.3.5 Preoperative a-adrenoceptor blockade. In 103 out of 112 patients treated with pbz the 
daily dosage was recorded. The final dosage for the entire group was 139 + 74 mg (mean + 
SD). Hypertensive patients received higher dose, 147 + 74 mg (n=94) than normotensive 
40 
ones, 92 + 52 mg (n=9). All patients received treatment until side-effects (ortostatism or nasal 
congestion) appeared. 
7.3.6 Surgery. A transabdominal approach was used in a vast majority of patients. 
Laparoscopic adrenalectomy was only performed in three patients, but is since 1997 the 
dominating technique for removal of benign PC at our hospital. Major bleeding, or intra­
operative arrhythmias, elicited by surgical tumour manipulation, was seen in 8 patients. 
Postoperative complications of clinical importance (re-bleeding, infection, or bowel 
obstruction) were only seen in 18 patients. There was no intra or postoperative mortality 
(within 30 d) within the entire series. One hundred twelve patients (104 PC, 8 PG) underwent 
unilateral adrenalectomy and 6 patients with bilateral tumours had bilateral procedures. Eight 
patients with juxta-adrenal PG underwent ipsi-lateral adrenalectomy; one patient underwent 
liver resection and two distal pancreatic resections due to the localization of PG. All MEN 2B 
patients had bilateral operations; in one case the cortical part of the adrenal was preserved 
unilaterally and in another patient bilaterally. Also one patient with VRD had bilateral 
operations with preservation of cortical tissue. Four patients underwent unilateral 
adrenalectomy due to typical symptoms, biochemical findings, or positive imaging MIBG 
studies compatible with PC. All had microscopic proof of adrenal medullary hyperplasia, 
confirmed by a point-counting morphometric analysis to assess adrenal medullary weight and 
volume. Estimated medullary weights were 1, 1, 2.4 and 3.4 g vs. glands from age and sex-
matched controls with a normal medullary weight of 0.3-0.5 g ( Jansson et a l 1988). These 
four patients with adrenal medullary hyperplasia were followed postoperatively for 16 + 3 yr 
with normal CA-levels and no symptoms. 
7.3.7 Histopathology. Four primary tumours had advanced local growth and were thus 
classified as malignant. These patients and 4 other patients with tumours histopathologically 
classified as benign developed metastases during follow-up. Eleven other patients had 
histopathological features suggestive of malignancy ("borderline risk"), but none of these 
patients developed metastases during an observation time of 11.5 + 6.5 yr. The mean weight 
of 113 tumours with recorded weight was 88 + 16 g. 
7.3.8 Outcome. The average follow-up for the 121 patients was 15 + 6 yr. Clinically 
malignant tumours were found among 8 patients with sporadic tumours, who developed 
metastases at a median of 6.5 yr (range 1-17 yr) after primary surgery [6/110 patients with PC 
(5.5%) and 2/11 patients with PG (18%)] (Table 8). None of the patients with malignant 
tumours had metastases at diagnosis. Four of these patients had repeat surgery with tumour 
removal/reduction. One female patient with PG (no. 35) recurred 15 yr after primary surgery 
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with para-aortic lymph node metastases, so she underwent nephrectomy and lymph nodes 
clearance and is alive with no evidence of disease 11 yr after repeat surgery. Two patients are 
alive with disease and one died of other causes. Four patients died of malignant PC 8, 9, 23 
and 30 yr after diagnosis, respectively. 
Table 8; Characteristics of 8 sporadic cases with malignant PC/PG 
Sex & Tumour Obs time Obs time 
age type* Unilat. Latency to Additional after l:st after primary 
(Pat. no) & site adx recurrence Treatment recurrence surgery Outcome 
F, 29 yr PC/Left * 1967 7yr Surgery 23 yr 30 yr DOD 
(17) (1974), dist + pbz 
M, 48 yr PC/Left 1968 17 yr pbz 6 yr 23 yr DOD 
(25) (1985), dist 
F, 22 yr PG/Left 1972 15 yr Surgery 11 yr 27 yr NED 
(35) (1987), loc 
F, 41 yr PC/Loft 1979 13 yr pbz 6 yr 20 yr A WD 
(54) (1992), dist 
F, 76 yr PC/Left* 1980 6 yr M1BG 2 yr 8 yr DOD 
(58) (1986), dist 
M, 61 yr PG/Left* 1982 4 & 6 yr Surgery 5yr 9 yr DOD 
(66) (1986), loc 
(1988), dist 
+ pbz 
M, 54 yr PC/Left* 1986 1 yr Surgery 11 yr 12 yr AWD 
(85) (1987), loc + pbz 
M, 59 yr PC/Right 1989 5 yr pbz 1 yr 5 yr OCD 
(95) (1994), dist 
DOD= Dead of disease adx= adrenalectomy loe= local recurrence 
NED= No evidence of disease pbz= phenoxybenzamine dist= distant metastases at diagnosis 
AWD= Alive with disease * Primary tumours with malignant histology 
OCD= Other cause of death 
Three patients with cortical tissue preservation have been observed without any need for 
corticosteroid substitution for 2, 4, and 18 yr, respectively. Two MEN 2 patients with bilateral 
PC were only operated on one side; one of these had a small second PC diagnosed without 
symptoms at high age, so surgery was withheld. In the other case a small contra-lateral PC 
was incidentally diagnosed at autopsy 9 yr after unilateral adrenalectomy. All patients with 
bilateral PC had hereditary disease and associated neuroectodermal abnormalities. The 5 
deceased patients with bilateral PC died of MTC/associated neuroectodermal diseases with a 
mean follow-up of 13.5 + 11.0 yr. 
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7.3.9 Survival analysis and causes of death, a) Regional series. Forty-two patients died 
during the observation period vs. 23.6 expected in the control population. The observed 
number of deaths was significantly higher than that in the control population (p< 0.001). 
Besides high age at primary surgery (p< 0.001), the only significant risk factor for death in 
this series was high urinary excretion of methoxy-CA (p= 0.018). Four patients died of 
malignant PC. Of 38 patients, who died from other causes than PC, 20 died of cardiovascular 
diseases and 7 died of causes not related to PC. In the remaining 11 patients, three MEN 2B 
patients died of MTC, three of intracranial tumours and 5 of other tumour diseases (Figure 
11). 
Figure 11: Clinical outcome of 121 patients with PC/PG (1950-1997) 
121 patients 
Dead 
42 = 36% 
A WD 
2 = 2% 
• 
NED 
77-62% 
OCD 
38 = 32% 
DOD Cardiovascular Diseases MTC 
4 = 4% 20 3 
* Myocardial infarction (n=12) 
* Stroke (iW) 
AWD - Alive with disease 
NED= No evidence of disease 
Intracranial tumours Other malignancies Other causes 
3 5 7 
* Meningeoma (n=l) * Pancreatic carcinoma * Trauma (n=2) 
* Glioblastoma (n=2) * Lung cancer * Intoxication (n==2) 
* Hepatocellular carcinoma * Hepatorenal syndrome 
* Epipharynx cancer * Hemorrhagic gastritis 
* Chronic lymphatic leukemia * Uraemia 
MTC= Medullary thyroid carcinoma DOD= Dead of disease 
OCD= Other causes of death 
At follow-up in 1997 42 patients had deceased, 2 patients were alive with disease and 77 patients had no 
evidence of disease. Four patients died of malignant PC/PG, but the main causes of death were cardiovascular 
diseases (n=20), PC/PG associated tumours (n=6) and other malignancies (n=5). Two patients who died of 
trauma had intracranial tumours at autopsy. 
The number of malignant tumours was relatively high and also the second most common 
cause of death; three patients had no tumour-related clinical symptoms and were first 
diagnosed at autopsy. Two patients, who died of other causes, had intracranial tumours at 
autopsy. Seventy-nine patients were alive at latest follow-up (16 + 11 yr); two with recurrent 
PC/PG and 77 with no evidence of disease. 
b) National series: Due to the findings of high tumour mortality and several other tumour 
diseases in Paper IV a large national series presumably without screening bias was collected 
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in order to study the validity of our findings. Using the Swedish NCR we found 481 clinically 
diagnosed adrenal PC between 1957-1997. The mean age at diagnosis of these patients was 
50.4 + 16.8 yr (range 2-89 yr). There were 222 men and 259 women in the series. The 
number of deaths in this cohort was 196, which was higher than the expected number of 153.4 
(p=0.001) (Table 9). 
Table 9: Expected and observed causes of death in patients with PC in Sweden (1958 — 97). 
Cause of death Sex Observed Expected Risk ratio 95% CI 
(confidence interval) 
Total 196 153.4 1.28 1.10-1.47 
All causes Men 102 108.8 0.94 0.76-1.14 
Women 94 44.6 2.11 1.70-2.60 
Total 95 26.2 3.63 2.94-4.44 
Tumour-related causes Men 48 14.1 3.41 2.51-4.52 
Women 47 12.1 3.90 2.86-5.18 
Total 44 60.5 0.73 0.53-0.98 
Cardiovascular causes Men 22 38.0 0.58 0.36-0.88 
Women 22 22.5 0.98 0.61-1.48 
Analyses of death causes showed that patients with PC had almost four times higher risk 
dying from a tumour disease vs. the general population. Similar risks were observed both for 
men and women (Risk ratio=3.4 and 3.9, respectively). There was no excess risk for death in 
cardiovascular diseases among patients with PC. In fact, there were only 22 deaths of 
cardiovascular disease in men vs. 38 expected. In women, the observed number was similar in 
the patient and control population. 
A second tumour disease subsequent to the diagnosis of PC was reported in 68 patients in the 
PC cohort vs. 31 expected in the control population (RR=2.20; CI=1.7-2.8). In men a second 
tumour disease was reported in 28 patients v.J. 13.6 expected (p=0.0008) and in women 40 vs. 
17.5 (p=0.000004). In men tumours of the liver/biliary tract (p=0.0072) and CNS tumours 
(p-0.00003) were most frequent. Among women malignant melanomas were highly over-
represented (p=0.007), likewise carcinomas of the uterine cervix (/>=0.002). On the other 
hand, in the general population breast cancer is common among women; the expected 
incidence was 5.2, but only four were reported in patients with PC (RR=0.75; CI=0.2-2.0). In 
men prostate cancer was expected in 3.6 vs. two found in patients with PC (RR=0.55; CI=0.1-
2.0) (Table 10). 
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Table 10: Expected and observed number of a second tumour disease in patients wit,h aPC. 
All Tumours of Malignant Carcinoma of 
tumours Liver & 
biliary system 
CNS melanoma Uterine 
cervix 
Breast Prostate 
Male Observed 28 3 6 2 2 
Expected 13.6 0.3 0.5 0.6 3.6 
Risk ratio 2.05 8.62 13.1 3.14 0.6 
CI 1.4-3.0 1.8-25.2 4.8-28.5 
Female Observed 40 llllllliilllllllll 0 4 5 4 
Expected 17.5 iiliiiiiiiliiili 0.5 0.6 0.7 5.2 
Risk ratio 2.29 0.00 6.61 7.7 0.8 
' 
CI 1.6-3.1 1.8-16.9 2.5-18.0 8 
CI= Confidence interval CNS= Central Nervous System 
7.3.10 Comments. In our regional consecutive series of patients with PC/PG with long 
follow-up we demonstrated that patients after successful treatment of PC/PG still had an 
increased mortality risk; twice as high as the matched Swedish population. The main causes 
of death in these patients were cardiovascular and tumour diseases. The relation between 
cardiovascular and tumour deaths was 1.3. The most common causes of death reported by the 
Swedish National Board of Health and Welfare are cardiovascular diseases (47-50%) 
followed by tumour diseases (23-25%), the relation was 2.0. The much lower ratio in our 
series of patients with PC/PG indicated that these patients more often died of tumour diseases. 
About half of the deceased patients w ith PC in our series died from other malignancies, not 
commonly found in the general population. Prostate cancer in men and breast cancer in 
females did not cause death of any patients with PC/PG in our series. 
In the national cohort, studied over a similar time period, we found that all patients treated for 
PC had a 4-fold increased tumour mortality risk compared with the general Swedish 
population. On the other hand, the risk of death in cardiovascular diseases was not elevated. 
The incidence of a second tumour disease, subsequent to the diagnosis of PC, in both men and 
women was more than twice higher than expected from control population. For men tumours 
of the liver/biliary tract and CNS tumours were most frequent. For women malignant 
melanomas and carcinomas of the uterine cervix were highly over-represented. Thus, the 
results from the national series of adrenal PC patients supported our findings from the 
regional series. 
Analysis of risk factors in the regional series showed that high age at primary surgery and 
elevated urinary levels of methoxy-CA were correlated with an increased risk for death during 
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long-term follow up. It is not surprising that high age is a risk factor, however we cannot 
explain why one separate CA-metabolite is also a risk factor. In other studies high secretion of 
DA, indicative of PG, has been associated with malignancy (John et al 1999). Surprisingly, 
pre- and postoperative hypertension was not correlated with increased death risk. Increased 
concentrations of circulating CA in patients with PC can contribute to vascular damage and 
arteriosclerosis (Pettersson et al 1990), which in association with stress can induce changes in 
lipoproteins, which further aggravate vascular changes and promote the arteriosclerosis 
process (Pettersson et al 1990, Bondjers et al 1991, Kaplan et al 1991). The result indicates 
that structurally and functionally altered blood vessels can contribute to higher risk for 
cardiovascular events, e.g. cerebral haemorrhage (Pacak 2001, Williams et al 2003). Thus, 
long exposure to CA excess prior to diagnosis of PC can cause irreversible vascular changes 
{Pettersson et al 1990) and explain the increased risk for cardiovascular death in patients with 
PC/PG without evident hypertension pre or postoperatively. In an interesting study from 
Göteborg (1970-1993) the death risk among 6810 normotensive vs. 686 hypertensive men on 
anti-hypertensive treatment was evaluated. There was no increased risk for death in the 
hypertensive group during the first decade of follow-up, but during the second decade this 
risk increased markedly, despite adequate blood pressure control. Significant risk factors for 
death in that study were elevated level of serum cholesterol, smoking and signs of target 
organ damage, but not hypertension before and after medical treatment {Andersson et al 
1998). 
The number of patients with persistent hypertension after successful surgery in PC/PG varies 
between different series {Sapienza et al 1999, Pacak 2001, McClellan 2002). Hypertension 
was cured by surgical removal of PC/PG in about half of our patients. Since all of these 
patients, except one, had normalized CA levels after surgery, vascular changes induced by CA 
excess prolonged hypertension prior to surgery is one possible explanation for persisting 
hypertension. Only one third of our hypertensive PC patients had adequate medical treatment 
after surgery, which illustrates the need of a hypertension clinic for these patients. 
In the present study no tumours with so called "borderline risk" histological features recurred 
after surgery. On the other hand, 4 of the patients who developed recurrent tumours during 
follow-up had none of these histological signs and were initially classified as benign. The 
number of histological benign PC/PG with malignant clinical course postoperatively was 
3.5% in the present series vs. 9% in other series {van Heerden et al 1990, Goldstein et al 
1999). 
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By creating large cohorts of patients with a rare disease with nearly complete follow-up and 
valid incidence figures, the NCR offers unique possibilities to analyse the risk for a second 
tumour disease. It also allows evaluation of the cause of death in a selected population vs. the 
general population. Autopsy-based death causes are reported separately, which allows 
separation of these cases from those clinically diagnosed. Thereby the risk for accidentally 
detected, clinically non-significant PC could be excluded. By definition the normal risk for 
death is the risk within the entire Swedish population with minimal risk for selection bias. The 
observed risks to develop other tumour diseases emphasize the importance of life-long 
follow-up of all PC/PG patients. 
Överrepresentation of neuroectodermal disorders among PC patient has previously been 
reported (Jansson et al 1988). A possible mechanism for such an association could be that 
genetic traits were more common than previously thought (Pacak 2001). Recent publications 
have indicated that the prevalence of germ-line mutations in cancer susceptibility genes in PC 
patients exceeded the earlier cited 10% {Neumann et al 2002, Bryant et al 2003). In hospital­
based studies, almost 20% of sporadic PC were associated with mutations in VHL (6%), 
SDHD (succinyl dehydrogenase subtype-D) (8%), SDHB (4%), or RET (<1%) (Bryant et al 
2003). In large population-based series, germ-line mutations in one of these 4 genes were 
found in 24% of patients with apparently sporadic PC (VHL=11%, RET=5%, SDHD=4% and 
SDHB=4%) (Neumann et al 2002). These data confirm that the number of hereditary PC has 
been underestimated (cf. Proye et al 1994). One explanation for such underestimation can be 
genetic imprinting, which means that individuals with genetic susceptibility for mutations in 
SDHD may not have a positive family history of PC/PG. One previous underestimation 
related to patients with MTC, of whom up to 25% had mutations of the RET proto-oncogene 
(Bryant et al 2003). Genetic testing is today strongly recommended for patients with MTC to 
identify MEN 2 patients at early Stage. As outlined by Neumann et al (2002) genetic testing 
of patients with "sporadic PC" to identify hereditary disease would be desirable for 
appropriate treatment (cortex-sparing surgery) and adequate long-term follow-up. 
PC was reported as a curable cause of hypertension (McClellan 2002), but even after 
successful surgery hypertension may persist (Plouin et al 1997). The age of patients at the 
time of diagnosis and the duration of hypertension before surgery will influence the results in 
different series. Young age and rapid normalization of blood pressure after surgery are factors 
favouring cure of hypertension, but sometimes it c an take more than one year to normalize 
blood pressure after surgery for PC (Sapienza et al 1999). Since patients with short history of 
hypertension (< 5 yr) are more likely to become normotensive after surgery, the success of 
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surgical treatment relies on early diagnosis (Simon et al 1993). The results from our series 
indicate that postoperative hypertension should be better managed and we think the best 
surveillance for these patients would be referral to a hypertension clinic. 
There are still no reliable predictors of malignancy other than occurrence of metastases and 
wide local invasion (Kebebew et al 1998, Goldstein et al 1999). Age, sex, symptoms, 
diagnostic delay, associated hereditary syndromes and hormonal excretion did not relate to 
malignancy {John et al 1999). Some large tumours may never metastasize, while some 
patients with small, presumably benign tumour die of distant metastasis (Pommier et al 1993). 
The role of DNA ploidy in diagnosis of malignant PC has given conflicting results (Pommier 
et al 1993, Shah et al 2003). Tumours with histological features normally predicting 
malignancy are often clinically benign as shown in our series and by others (van Heerden et 
al 1990, Lack 1997, Goldstein et al 1999). The reported rates of malignancy vary largely due 
to the rarity of PC/PG, small series, and short follow-up (Proye et al 1994). Series with high 
numbers of malignant PC are usually from referral centres with accumulation of malignant 
PC in a non-consecutive manner (Goldstein et al 1999). In this respect our series with one 
centre responsible for the adrenal surgery in one geographical region is probably unique and 
may better represent the true biological nature of PC/PG. 
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8. Conclusions 
> Our treatment strategy for ACC combined active surgical treatment, monitored adjuvant 
mitotane therapy and attempts to early detect recurrence by urinary steroid profiles. In a 
consecutive series with an almost equal ratio between low and high Stage tumours, the 5-
year survival clearly exceeded 50%. The use of adjuvant mitotane requires multicenter 
randomized studies for evaluation. 
> For patients with advanced, or non-resectable, ACC there is no evidence that single agent 
chemotherapy is useful. Multiple agent chemotherapy with addition of mitotane seems to 
be associated with better survival. Protocols to find the best multiple agent chemotherapy 
combined with mitotane in a multicenter trial are in preparation. 
^ Medullary and cortical adrenal tumours express specific patterns of CAM. Down-
regulation of NCAD indicates malignant behaviour of cortical tumours. High expressions 
of K.i-67 and high mitotic index in ACC are useful in distinguishing between malignant 
and benign adrenocortical tumours. 
^ Despite successful surgical removal of PC these patients run an increased risk for death 
during long-term follow-up. Less than half of the patients were relieved of hypertension 
after surgery. Cardiovascular diseases and other malignancies were the main causes of 
death. 
y Certain tumour diseases were overrepresented after PC had been diagnosed. Therefore, 
life-long follow-up of patients with PC cannot only reveal recurrence and cardiovascular 
diseases, but can also be helpful for detection of other malignancies. 
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